Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer

P. M. Gocze, D. G. Szabo, G. N. Than, I. F. Csaba, G. Keller, H. Vahrson, H. Bohn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PP-4, a recently characterized glycoprotein from human placenta was studied using a specific double-antibody radioimmunoassay in sera of 130 volunteers, 74 cervical cancer patients and 43 endometrial cancer patients. Elevated levels (>3 μg/l) were found in 35 (47.3%) cervical cancer patients and in 18 (41.9%) endometrial cancer patients. Degree of elevation were not correlated with clinical stage, histology, and histological degree of differentiation. 36 patients with cervical cancer and 20 patients with endometrial cancer were monitored on two to seven occasions during four to 50 weeks. Rising, remaining unchanged of falling levels of PP-4 correlated with progression, stabilization or regression of disease 55.5% in patients with cervical and 65.0% in patients with endometrial cancer. During and some months after external telecobalt irradiation therapy wide range of PP-4 levels were observed in some patients. The study suggest that PP-4 can be regarded as a tumor associated protein which most likely can serve as tumor marker in cervical and endometrial cancer.

Original languageEnglish
Pages (from-to)538-544
Number of pages7
JournalStrahlentherapie und Onkologie
Volume167
Issue number9
Publication statusPublished - Jan 1 1991

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Fingerprint Dive into the research topics of 'Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer'. Together they form a unique fingerprint.

  • Cite this

    Gocze, P. M., Szabo, D. G., Than, G. N., Csaba, I. F., Keller, G., Vahrson, H., & Bohn, H. (1991). Initial experience with placental protein 4 (PP-4) as tumor marker in cervical and endometrial cancer. Strahlentherapie und Onkologie, 167(9), 538-544.